# Clinical Trial Matching Service

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Chief Research Officer
**Purpose**: Connect AATD patients with relevant clinical trials and research studies to advance science while providing patients access to cutting-edge treatments

---

## ðŸ“‹ Table of Contents

1. [Service Overview](#service-overview)
2. [Why Clinical Trials Matter](#why-clinical-trials-matter)
3. [Trial Database](#trial-database)
4. [Matching Process](#matching-process)
5. [Patient Support](#patient-support)
6. [Researcher Services](#researcher-services)
7. [Travel Assistance](#travel-assistance)
8. [Success Metrics](#success-metrics)

---

## Service Overview

### What We Offer

**Mark Egly Foundation Clinical Trial Matching Service** connects AATD patients with clinical trials and research studies:

**Services Include**:

- âœ… **Trial Database**: Searchable database of all active AATD clinical trials (updated weekly)
- âœ… **Eligibility Screening**: Determine if patient qualifies for specific trials (pre-screening questionnaire)
- âœ… **Trial Navigation**: Explain trial details (purpose, risks/benefits, time commitment, compensation)
- âœ… **Enrollment Coordination**: Connect patient with trial site, assist with enrollment process
- âœ… **Travel Grants**: Financial assistance for patients enrolled in trials requiring travel
- âœ… **Patient Registry**: Opt-in registry for patients willing to be contacted about future trials
- âœ… **Researcher Recruitment**: Help researchers recruit AATD patients for studies

**Who Can Use**:

- **Patients**: Anyone with AATD or suspected AATD (some trials accept carriers, family members)
- **Researchers**: Scientists recruiting AATD patients for clinical trials or observational studies
- **No cost** to patients (Foundation service is free; trials may offer compensation)

---

### Service Goals

**Year 1** (2026):

- Database: 25+ active trials listed
- Match 100 patients to trials (50 enrolled)
- Patient Registry: 500 patients enrolled
- Travel grants: $25K awarded (50 patients)

**Year 3** (2028):

- Database: 50+ active trials
- Match 500 patients/year (250 enrolled)
- Patient Registry: 2,500 patients
- Travel grants: $100K/year

**Year 5** (2030):

- Database: 75+ active trials
- Match 1,000 patients/year (500 enrolled)
- Patient Registry: 10,000 patients (comprehensive AATD registry)
- Travel grants: $250K/year
- Foundation-sponsored trials (Mark Egly Foundation funds investigator-initiated trials)

---

## Why Clinical Trials Matter

### For Patients: Access to Cutting-Edge Treatments

**Benefits of Participating in Clinical Trials**:

- âœ… **Early Access**: New treatments years before FDA approval (gene therapy, novel AAT formulations, anti-inflammatory drugs)
- âœ… **Expert Care**: Close monitoring by top specialists (free tests, exams, medications)
- âœ… **No Cost**: Investigational drug + trial-related care are free (insurance not billed)
- âœ… **Compensation**: Many trials pay for time/travel ($50-$500 per visit)
- âœ… **Altruism**: Help future AATD patients (advance science)
- âœ… **Hope**: For patients with advanced disease (trials may be last chance)

**Common Misconceptions** (Foundation Educates Patients):

- âŒ **"I'll get a placebo"**: Many trials have open-label extensions (everyone gets drug eventually)
- âŒ **"It's too risky"**: Trials have rigorous safety monitoring (IRB, data safety monitoring boards)
- âŒ **"I'll be a guinea pig"**: Informed consent protects patient rights; patients can withdraw anytime
- âŒ **"Trials are only for desperate patients"**: Trials enroll patients at all disease stages (early-stage trials prevent progression)

---

### For Research: Accelerate AATD Cure

**Patient Recruitment is Biggest Barrier**:

- **80% of clinical trials fail to meet enrollment goals** (delays, increased costs, trial cancellation)
- **Average trial enrollment rate**: 10-20% of eligible patients (most patients never hear about trials)
- **AATD-specific challenge**: Small patient population (100K-200K in US) â†’ even harder to recruit

**Foundation's Impact**:

- âœ… **Awareness**: Promote trials to AATD community (email, social media, events)
- âœ… **Pre-Screening**: Reduce researcher burden (Foundation screens patients before referral)
- âœ… **Trust**: Foundation endorsement increases patient willingness (trusted intermediary)
- âœ… **Speed**: Faster enrollment â†’ faster results â†’ faster FDA approval â†’ cure sooner

---

### Types of AATD Trials

**1. Gene Therapy Trials** ðŸ”¬ (Most Promising):

- **Goal**: Fix genetic defect (replace mutant SERPINA1 gene with functional gene)
- **Approach**: One-time infusion (AAV vector delivers corrected gene to liver)
- **Status**: Phase 1/2 trials ongoing (Vertex, Verve, Intellia, Takeda)
- **Impact**: POTENTIAL CURE (permanent fixâ€”no more weekly infusions)

**2. Augmentation Therapy Trials**:

- **New Formulations**: Once-monthly IV (instead of weekly), subcutaneous (instead of IV), inhaled AAT
- **Examples**: Kamada (once-monthly IV), Grifols (subcutaneous), Takeda (inhaled)
- **Impact**: Improve convenience, reduce infusion burden

**3. Anti-Inflammatory Trials**:

- **Goal**: Reduce lung inflammation (slow emphysema progression)
- **Drugs**: PI3K inhibitors, chemokine receptor antagonists, anti-IL-8 antibodies
- **Impact**: Complement augmentation therapy (target inflammation, not just protein replacement)

**4. Liver Disease Trials**:

- **Goal**: Reduce ZZ protein accumulation in liver (prevent cirrhosis)
- **Drugs**: RNAi (silence mutant gene), small molecules (enhance ZZ protein degradation)
- **Examples**: Arrowhead (RNAi), Dicerna (RNAi)
- **Impact**: Prevent liver disease (currently no FDA-approved treatment for AATD liver disease)

**5. Observational Studies** (Non-Interventional):

- **Goal**: Track disease progression, quality of life, treatment outcomes
- **Examples**: AATD Registry studies, natural history studies
- **Impact**: Understand disease â†’ inform future trial design

---

## Trial Database

### Database Features

**Comprehensive Listing**:

- All active AATD trials (US + international)
- Updated weekly (new trials added, completed trials removed)
- Sources: ClinicalTrials.gov, EudraCT (European registry), sponsor press releases

**Searchable Filters**:

- **Trial Type**: Gene therapy, augmentation therapy, anti-inflammatory, liver, observational
- **Phase**: Phase 1, 2, 3, 4
- **Location**: By state, city, or distance from zip code
- **Eligibility**: Age, genotype (ZZ, SZ, etc.), disease severity (FEV1 range), treatment status (on augmentation therapy or not)
- **Sponsor**: Pharma company (Vertex, Takeda, etc.) or academic institution

**Trial Details** (For Each Listing):

- **Title**: Official trial name + lay-friendly description
- **Purpose**: What the trial is testing (1-2 sentences)
- **Eligibility Criteria**: Who can participate (age, genotype, FEV1, smoking status, etc.)
- **Study Design**: Randomized? Placebo-controlled? Open-label?
- **Duration**: How long (weeks, months, years)
- **Time Commitment**: # of visits, frequency, time per visit
- **Location**: Trial sites (cities, addresses)
- **Compensation**: Payment for participation (if any)
- **Contact**: Trial coordinator (phone, email)
- **Enrollment Status**: Recruiting, enrolling, closed, completed

---

### Database Access

**Public Website**:

- MarkEglyFoundation.org/ClinicalTrials
- Anyone can search (patients, caregivers, healthcare providers)
- No login required (open access)

**Mobile-Friendly**:

- Responsive design (works on phones, tablets)
- Location-based search (automatically detect user's location, show nearby trials)

**Email Alerts**:

- Patients can sign up for alerts (notified when new trials matching their profile are posted)
- Frequency: Weekly digest or immediate (patient preference)

---

### Example Trial Listing

```
TRIAL: Gene Therapy for Alpha-1 Antitrypsin Deficiency (Vertex Pharmaceuticals)

WHAT IT IS:
A Phase 1/2 clinical trial testing a one-time gene therapy (VX-634) that could potentially cure
AATD by replacing the faulty gene with a functional one.

WHO CAN PARTICIPATE:
- Age 18-65
- Genotype: ZZ only
- FEV1: 40-80% predicted
- Non-smoker (or quit 12+ months ago)
- NOT on augmentation therapy (must discontinue 6 months before enrollment)

WHAT'S INVOLVED:
- 1 infusion (one-time, 2-hour IV infusion of gene therapy)
- 15 study visits over 2 years (more frequent in first 6 months)
- Blood draws, liver biopsies (baseline and 12 months), lung function tests
- Close monitoring for safety

RISKS:
- Liver enzyme elevation (temporary, usually resolves)
- Immune response to gene therapy vector
- Unknown long-term effects (first-in-human study)

BENEFITS:
- Potential cure (no more weekly infusions)
- AAT levels increase to normal range (within 3 months, in early studies)
- No cost (all study-related care is free)
- Compensation: $100 per visit ($1,500 total)

LOCATIONS:
- Boston, MA (Massachusetts General Hospital)
- Denver, CO (National Jewish Health)
- San Francisco, CA (UCSF)

STATUS: Actively enrolling (goal: 30 patients)

CONTACT:
Trial Coordinator: (555) 123-4567
Email: VX634trial@vertex.com

LEARN MORE:
ClinicalTrials.gov ID: NCT05678910
Mark Egly Foundation Trial Navigator: 1-800-AATD-TRIAL
```

---

## Matching Process

### Step-by-Step Matching

**Step 1: Patient Inquiry**:

- Patient searches database (finds trial of interest)
- OR Patient calls Foundation (1-800-AATD-TRIAL)â€”Trial Navigator helps search

**Step 2: Pre-Screening Questionnaire**:

- Foundation administers questionnaire (10-15 min, phone or online)
- Questions:
  - Demographics (age, location)
  - AATD details (genotype, AAT level, diagnosis date)
  - Medical history (lung function, liver disease, comorbidities)
  - Current treatments (augmentation therapy, oxygen, medications)
  - Smoking status (current, former, never)
  - Willingness to travel (how far? overnight stays?)
- Foundation determines if patient meets basic eligibility (before referring to trial site)

**Step 3: Trial Site Referral**:

- If patient appears eligible, Foundation contacts trial site
- Provides patient's contact info + pre-screening summary (with patient's consent)
- Trial coordinator calls patient (within 3-5 business days)

**Step 4: Formal Screening**:

- Trial site conducts formal screening (detailed medical history, tests)
- May require in-person visit (screening visitâ€”lung function, blood work, imaging)
- Determines final eligibility

**Step 5a: Enrolled** âœ…:

- Patient signs informed consent
- Begins trial participation
- Foundation follows up (check in at 1 month, 6 months, end of trial)

**Step 5b: Not Eligible** âŒ:

- Trial site explains why (doesn't meet criteria, too many participants enrolled, etc.)
- Foundation offers alternative trials (if available) or adds patient to registry (for future trials)

---

### Trial Navigator Support

**What Trial Navigators Do**:

- âœ… **Explain Trials**: Demystify clinical trial process (what to expect, risks/benefits)
- âœ… **Match Patients**: Search database, identify suitable trials
- âœ… **Pre-Screen**: Administer questionnaire, determine eligibility
- âœ… **Coordinate**: Connect patient with trial site
- âœ… **Support**: Answer questions, address concerns, follow up

**Qualifications**:

- Nurse or Patient Navigator (clinical background)
- Trained in clinical trial process (informed consent, GCP, HIPAA)
- Knowledge of AATD (disease, treatments, research landscape)

**Availability**:

- Phone: 1-800-AATD-TRIAL (M-F, 9am-5pm ET)
- Email: trials@markeglyfoundation.org (response within 24 hours)

---

## Patient Support

### Education & Informed Decision-Making

**Resources Provided**:

**1. Clinical Trials 101 Guide** (PDF, 20 pages):

- What is a clinical trial?
- Phases of trials (1, 2, 3, 4)
- Informed consent process
- Risks and benefits
- Patient rights (can withdraw anytime, no penalty)
- Questions to ask before enrolling

**2. AATD-Specific Trial Guide** (PDF, 15 pages):

- Overview of AATD research landscape
- Types of AATD trials (gene therapy, augmentation therapy, etc.)
- What to expect (typical visit schedule, tests, time commitment)
- Financial considerations (compensation, travel costs)

**3. Trial Comparison Tool** (Online):

- Compare multiple trials side-by-side (eligibility, location, time commitment, compensation)
- Help patients decide which trial is best fit

**4. Video Testimonials**:

- AATD patients who participated in trials (share experiences, dispel fears)
- Researchers explain trials (lay-friendly language)

---

### Emotional Support

**Common Patient Concerns**:

- ðŸ˜° **Fear of Unknown**: "What if something goes wrong?"
- ðŸ˜° **Placebo Anxiety**: "What if I get placebo and don't benefit?"
- ðŸ˜° **Time Commitment**: "Can I juggle trial visits with work/family?"
- ðŸ˜° **Travel Burden**: "I can't afford to travel to trial site"

**Foundation Support**:

- âœ… **Peer Counseling**: Connect with patients who've participated in trials (Buddy Systemâ€”see separate doc)
- âœ… **Trial Navigator**: 1:1 counseling (discuss concerns, weigh pros/cons)
- âœ… **Support Groups**: Virtual support group for trial participants (share experiences, tips)

---

## Researcher Services

### Trial Recruitment Support

**What Foundation Offers Researchers**:

**1. Trial Promotion**:

- List trial in Foundation's database (high-visibility to AATD community)
- Email blast to Foundation's mailing list (5,000+ AATD patients, Year 1 â†’ 50,000+, Year 5)
- Social media promotion (Facebook, Twitter, Instagramâ€”Foundation's channels)
- Event promotion (annual patient conference, support groupsâ€”hand out trial flyers)

**2. Pre-Screening**:

- Foundation screens patients (administer pre-screening questionnaire)
- Refer only eligible patients (reduce researcher's screening burden)
- Estimated time saved: 50% (researcher screens 200 patients â†’ Foundation pre-screens, refers 100 eligible â†’ researcher screens 100)

**3. Patient Registry Access**:

- Researchers can query Foundation's patient registry (filter by genotype, disease stage, location)
- Send recruitment invitations to matched patients (via Foundationâ€”patient privacy protected)

**4. Education & Engagement**:

- Foundation educates patients about trial importance (increase willingness to participate)
- Warm hand-off (Foundation introduces patient to researcherâ€”builds trust)

---

### Cost to Researchers

**Year 1-2**: **FREE** (Foundation builds reputation, establishes relationships)

**Year 3+**: **Tiered Pricing** (to sustain program):

- **Academic Researchers**: Free (promote investigator-initiated trials)
- **Small Biotech**: $5K-$10K per trial (listing + promotion for 12 months)
- **Large Pharma**: $25K-$50K per trial (listing + promotion + dedicated recruitment support)
- **Registry Access**: $50K/year (unlimited queries, recruitment invitations)

**Revenue Projection** (Year 5):

- 10 pharma-sponsored trials Ã— $35K avg = $350K
- 5 registry access subscriptions Ã— $50K = $250K
- Total: $600K/year (fund patient servicesâ€”travel grants, patient registry maintenance)

---

## Travel Assistance

### Trial Travel Grant Program

**Problem**: Many trials are at specialized research centers (limited locationsâ€”Boston, Denver, SF, etc.)

**Patient Barrier**: Can't afford travel (flights, hotels, meals, parking, lost wages)

**Foundation Solution**: **Travel Grants** (up to $2,500 per patient per trial)

---

### Grant Eligibility

**Who Qualifies**:

- âœ… Enrolled in AATD clinical trial (confirmed by trial site)
- âœ… Trial requires travel > 100 miles from home
- âœ… Financial need (income < 300% federal poverty levelâ€”~$90K for family of 4)

**Covered Expenses**:

- âœ… Transportation (flights, gas mileage, train, rental car)
- âœ… Lodging (hotelâ€”up to $150/night)
- âœ… Meals (per diemâ€”up to $50/day)
- âœ… Parking/tolls
- âŒ NOT covered: Lost wages (some trials compensate for time, but Foundation doesn't)

---

### Grant Process

**Step 1: Apply**:

- Submit application (online formâ€”trial details, travel distance, estimated costs)
- Proof of enrollment (letter from trial coordinator)
- Financial documentation (tax return, pay stubsâ€”verify need)

**Step 2: Approval**:

- Foundation reviews (5-7 business days)
- If approved, issue travel grant (check or direct deposit)

**Step 3: Travel**:

- Patient travels to trial site
- Keep receipts (hotel, gas, etc.)

**Step 4: Reimbursement**:

- Submit receipts (within 30 days of travel)
- Foundation reimburses actual expenses (up to grant amount)

---

### Grant Budget

**Year 1**:

- 50 patients Ã— $500 avg travel costs per patient = $25K

**Year 3**:

- 200 patients Ã— $500 avg = $100K

**Year 5**:

- 500 patients Ã— $500 avg = $250K

**Funding Sources**:

- Corporate sponsors (pharma companiesâ€”sponsor travel grant program)
- Major donors (dedicate gifts to trial travel fund)
- Trial revenue (charge pharma companies for recruitment â†’ use revenue to fund travel grants)

---

## Success Metrics

### Track Monthly

**Patient Reach**:

- # of patients using trial database (unique visitors/month)
- # of patients matched to trials (referred to trial sites)
- # of patients enrolled (confirmed by trial sites)
- Enrollment rate (% of referred patients who enrollâ€”goal: 50%)

**Trial Database**:

- # of active trials listed
- Database update frequency (goal: weekly)
- Most viewed trials (identify high-interest trials)

**Patient Registry**:

- # of patients enrolled in registry
- Registry demographics (genotype, age, disease stage, location)
- # of registry queries by researchers

**Travel Grants**:

- # of travel grants awarded
- Average grant amount
- Total $ awarded (YTD)
- % of grant recipients who complete trial (retention)

**Researcher Satisfaction**:

- # of trials promoted by Foundation
- Enrollment improvement (pre-Foundation vs. with Foundation support)
- Researcher testimonials

---

### Year 1 Targets

**Patient Reach**:

- 100 patients matched to trials
- 50 patients enrolled (50% conversion)
- 500 patients in patient registry

**Trial Database**:

- 25 active trials listed
- 1,000 website visits/month

**Travel Grants**:

- 50 grants awarded
- $25K total awarded

**Researcher Partnerships**:

- 5 pharma/biotech partnerships
- 3 academic researcher partnerships

---

## Summary

**Mark Egly Foundation Clinical Trial Matching Service**:

- âœ… **Comprehensive Trial Database**: All active AATD trials (updated weekly)
- âœ… **Personalized Matching**: Trial Navigators help patients find suitable trials
- âœ… **Travel Grants**: Financial assistance for patients traveling to trial sites
- âœ… **Patient Registry**: Opt-in registry for future trial recruitment
- âœ… **Researcher Support**: Promote trials, pre-screen patients, accelerate enrollment

**This service is CRITICAL for BOTH patients and researchers**:

- **Patients**: Access to cutting-edge treatments, hope for cure
- **Researchers**: Faster enrollment â†’ faster results â†’ faster FDA approval â†’ CURE

**Together, we accelerate the path to an AATD cure.**

---

**Want to Participate in a Trial?**

**Mark Egly Foundation Clinical Trial Matching Service**
ðŸ“ž Phone: 1-800-AATD-TRIAL
ðŸ“§ Email: trials@markeglyfoundation.org
ðŸŒ Website: MarkEglyFoundation.org/ClinicalTrials

---

**Approved by**: Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"Accelerating the cure, one patient at a time."_

**â€” Mark Egly Foundation**
